Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Using human genetics to make new medicines

Nature Reviews Genetics volume 16, pages 561–562 (2015)Cite this article

Subjects

Abstract

Jeffrey Barrett, Ian Dunham and Ewan Birney discuss the initiatives of the newly founded Centre for Therapeutic Target Validation, including a range of approaches to use human genetics to inform drug discovery and make better medicines.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40–51 (2014).

    Article  CAS  Google Scholar 

  2. Nelson, M. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 45, 856–860 (2015).

    Article  Google Scholar 

  3. Monteleone, G. et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N. Engl. J. Med. 372, 1104–1113 (2015).

    Article  CAS  Google Scholar 

  4. Jostins, L. et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).

    Article  CAS  Google Scholar 

  5. Davey-Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet. 23, R89–R98 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Therapeutic Target Validation,

    Jeffrey C. Barrett & Ian Dunham

  2. Wellcome Trust Sanger Institute,

    Jeffrey C. Barrett & Ian Dunham

  3. European Molecular Biology Laboratory European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK

    Jeffrey C. Barrett, Ian Dunham & Ewan Birney

Authors
  1. Jeffrey C. Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian Dunham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ewan Birney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey C. Barrett.

Ethics declarations

Competing interests

E.B. is a paid consultant for Oxford Nanopore, a DNA sequencing company. J.C.B. and I.D. declare no competing interests.

Related links

Related links

FURTHER INFORMATION

Accelerating Medicines Partnership

Centre for Therapeutic Target Validation

Genomics England

Precision Medicine Initiative

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barrett, J., Dunham, I. & Birney, E. Using human genetics to make new medicines. Nat Rev Genet 16, 561–562 (2015). https://doi.org/10.1038/nrg3998

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrg3998

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research